Skip to main navigation Skip to search Skip to main content

BAYER CORP: EFFECTS OF DIFFERENT DOSE REGIMENS OF IGIV-CHROMATOGRAPHY 91GIV-C, 10% TREATMENT ON RELAPSES IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS

Project: Research

Project Details

StatusFinished
Effective start/end date12/17/02 → 10/26/06

Funding

  • PRA International Incorporated: $132,204.00